A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of ...

The confirmed presence of substandard or falsified anticancer medicines in sub-Saharan Africa will complicate cancer care.

Colorectal cancer is one of the most common tumors among people over the age of 50. Although it is known to develop from ...

The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For ...

Scientists have identified a new anti-ageing drug class that works by acting on a key gut bacteria ... which inhibits TOR and is under investigation for its anti-cancer properties. Researchers found ...

Colorectal cancer is one of the most common tumors among people over the age of 50. Although it is known to develop from small lesions or polyps, its exact causes are unknown — only a few risk factors ...

Recent studies presented at the European Society for Medical Oncology meeting showcase promising results of antibody-drug conjugates (ADCs) in breast cancer treatment. Trials reveal significantly ...

Colorectal cancer is one of the most common tumours among people over the age of 50. Although it is known to develop from ...

Research reveals that the combination of palbociclib and telaglenastat, two drugs with complementary actions, could help ...

Adding abemaciclib to standard endocrine therapy reduces the risk of death and recurrence in patients with breast cancer.

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...